Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 6/20 | 0.45 |
| ▸ | IDO1 | P14902 | 9/20 | 0.41 |
| ▸ | TDO2 | P48775 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2818204 | 1.00 | CYP11B2 (0.45) | CYP11B2IDO1TDO2CYP3A4HSD11B1 | |
| SCHEMBL2818201 | 1.00 | CYP11B2 (0.45) | CYP11B2IDO1TDO2CYP3A4HSD11B1 | |
| SCHEMBL2820997 | 0.97 | CYP11B2 (0.41) | CYP11B2IDO1TDO2CYP3A4HSD11B1 | |
| SCHEMBL2820348 | 0.97 | CYP11B2 (0.41) | CYP11B2IDO1TDO2CYP3A4HSD11B1 | |
| SCHEMBL2820351 | 0.97 | CYP11B2 (0.41) | CYP11B2IDO1TDO2CYP3A4HSD11B1 | |
| SCHEMBL2817728 | 0.92 | CYP11B2 (0.43) | CYP11B2IDO1TDO2CYP3A4 | |
| SCHEMBL2817700 | 0.84 | CYP11B2 (0.43) | CYP11B2HSD11B1CYP19A1 | |
| SCHEMBL9493435 | 0.84 | CYP11B2 (0.43) | CYP11B2HSD11B1CYP19A1 | |
| SCHEMBL9493247 | 0.84 | CYP11B2 (0.43) | CYP11B2HSD11B1CYP19A1 | |
| SCHEMBL9805000 | 0.83 | CYP11B2 (0.46) | CYP11B2IDO1TDO2CYP3A4HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436035-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-05-07 | — | — | US | disclosed |
| US-20100048562-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048562-A1 | ORGANIC COMPOUNDS | CYP11B1, HSD11B1, CYP17A1 | CYP11B2 6/4885IDO1 1361/4885TDO2 1757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.